NCT02225704 2026-04-13
Radium-223 in Combination With Enzalutamide
Cancer Trials Ireland
Phase 2 Completed
Clinical Trials
12 trialsNCT04206319 2026-03-16
Radium-223 in Biochemically Recurrent Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT04704505 2026-02-06
BAT-RAD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT05133440 2026-01-21
A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05924672 2026-01-14
Efficacy of Ra-223 in PSMA PET Optimally Selected Patients
University of California, San Francisco
Phase 2 Active not recruiting
NCT04037358 2025-12-19
RAVENS
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03093428 2025-03-28
Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03002220 2024-12-11
EXCAAPE
MedSIR
Phase 2 Completed
NCT03230734 2024-09-27
RAPSON
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Active not recruiting
NCT02278055 2023-04-07
Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03305224 2021-09-09
CORE-OCU
Osaka City University
Phase 2 Unknown
NCT02463799 2021-07-08
Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed